Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study

• Patrick K. Reville,
• Hagop M. Kantarjian,
• Farhad Ravandi,
• Elias Jabbour,
• Courtney D. DiNardo,
• Naval Daver,
• Naveen Pemmaraju,
• Maro Ohanian,
• Yesid Alvarado,
• Lianchun Xiao,
• Gheath Alatrash,
• Sanam Loghavi,
• Caitlin R. Rausch,
• Gautam Borthakur,
• Marina Konopleva,
• Jorge Cortes,
• Tapan M. Kadia

Affiliations

Patrick K. Reville

Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

Hagop M. Kantarjian

Department of Leukemia, The University of Texas MD Anderson Cancer Center

Farhad Ravandi

Department of Leukemia, The University of Texas MD Anderson Cancer Center

Elias Jabbour

Department of Leukemia, The University of Texas MD Anderson Cancer Center

Courtney D. DiNardo

Department of Leukemia, The University of Texas MD Anderson Cancer Center

Naval Daver

Department of Leukemia, The University of Texas MD Anderson Cancer Center

Naveen Pemmaraju

Department of Leukemia, The University of Texas MD Anderson Cancer Center

Maro Ohanian

Department of Leukemia, The University of Texas MD Anderson Cancer Center

Yesid Alvarado

Department of Leukemia, The University of Texas MD Anderson Cancer Center

Lianchun Xiao

Department of Biostatistics, The University of Texas MD Anderson Cancer Center

Gheath Alatrash

Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center

Sanam Loghavi

Department of Hematopathology, The University of Texas MD Anderson Cancer Center

Caitlin R. Rausch

Division of Pharmacy, The University of Texas MD Anderson Cancer Center

Gautam Borthakur

Department of Leukemia, The University of Texas MD Anderson Cancer Center

Marina Konopleva

Department of Leukemia, The University of Texas MD Anderson Cancer Center

Jorge Cortes

Georgia Cancer Center, Augusta University

Tapan M. Kadia

Department of Leukemia, The University of Texas MD Anderson Cancer Center